Evaluation of Oral Factor Xa inhibitor-associated Extracranial Bleeding Reversal with Andexanet alfa.

CONCLUSION: We report poor overall outcomes, a low rate of hemostatic effectiveness, and a high rate of ischemic complications and mortality in this retrospective analysis of oral FXa inhibitor reversal with andexanet alfa for extracranial bleeds. More rigorous epidemiological, and ideally randomized studies are needed to determine the role of andexanet alfa for FXa inhibitor-associated bleeding for extracranial hemorrhages, where large variation in severity and presentation exists.
PMID: 32738161 [PubMed - as supplied by publisher]

Source: Thrombosis and Haemostasis - July 31, 2020 Category: Hematology Authors: Nederpelt CJ, Naar L, Sylvesterc KW, Barra ME, Roberts RJ, Velmahos GV, Kaafarani HMA, Rosenthal MG, King DR Tags: J Thromb Haemost Source Type: research